BiotechTube

Erlotinib

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epidermal Growth Factor Receptor

Conditions

Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer

Trial Timeline

Jun 1, 2016 → Jun 19, 2019

NCT ID
NCT02770014

About Erlotinib

Erlotinib is a phase 2 stage product being developed by Astellas Pharma for Epidermal Growth Factor Receptor. The current trial status is terminated. This product is registered under clinical trial identifier NCT02770014. Target conditions include Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (5)

NCT IDPhaseStatus
NCT02770014Phase 2Terminated
NCT01967095Phase 1Completed
NCT01573702Phase 2Completed
NCT01247922Phase 2Terminated
NCT01116336Phase 1Completed

Competing Products

13 competing products in Epidermal Growth Factor Receptor

See all competitors
ProductCompanyStageHype Score
HER3-DXdDaiichi SankyoPre-clinical
23
radio-labeled naquotinib + naquotinibAstellas PharmaPhase 1
33
KRN23Kyowa KirinPhase 2
52
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
ABT-414AbbViePre-clinical
23
Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)MerckPhase 3
77
Venetoclax + FulvestrantRochePhase 2
52
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, CapecitabineRochePhase 3
77
Palbociclib + Everolimus + ExemestanePfizerPhase 1/2
40
PaliferminSwedish Orphan BiovitrumPhase 1/2
40
Crysvita (burosumab-twza) TreatmentUltragenyx PharmaceuticalApproved
80
FDX104 (4% Doxycycline)Vyne TherapeuticsPhase 2
44
ATR-04AzitraPhase 1/2
33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85